Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06334731 · ClinicalTrials.gov registry record

Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic

A clinical trial, sponsored by Methodist Health System.

Completed
Registry status
400
Enrollment target

NCT06334731: Completed study, sponsored by Methodist Health System.

NCT06334731 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 400 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06334731 has completed, sponsored by Methodist Health System.

COMPLETED
Registry status
400 participants
Enrollment target

Study Summary

Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.

Primary Outcome

Incidence of third generation cephalosporin-resistant bacteria (3GCRB)

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2021-07-06
Est. Completion 2025-07-14
Methodist Health System

125 total trials

What the finished NCT06334731 record still lists

NCT06334731 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT06334731 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06334731 about?

NCT06334731 is a clinical study titled "Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic". Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.

What is the current status of trial NCT06334731?

This trial is currently completed. The enrollment target is 400 participants. The study started on 2021-07-06. Estimated completion is 2025-07-14.

Who is sponsoring clinical trial NCT06334731?

This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06334731, the US trial registry maintained by the National Library of Medicine. NCT06334731 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.